Skip to main content
Wolfson Institute of Population Health

Professor Alastair Noyce, BMedSci, MB BS, MSc, MRCP, PhD, FHEA


Professor in Neurology and Neuroepidemiology and Consultant Neurologist



I am the Professor in Neurology and Neuroepidemiology in the Centre for Preventive, Detection and Diagnosis (CPDD), in the Wolfson Institute of Population Health, Queen Mary University of London (QMUL). I am the Lead of the Preventive Neurology Unit (PNU) based within CPDD and a Consultant Neurologist at Barts Health NHS Trust.

 I graduated from Barts and the London (QMUL) in 2007 and I pursued integrated training via the Foundation Academic Programme and an NIHR Academic Clinical Fellowship at UCL. Between 2012-2016 I undertook a PhD in Neuroscience at UCL and between 2014-2016 I undertook an MSc in Epidemiology at London School of Hygiene and Tropical Medicine. I re-joined QMUL and the PNU in 2017 to lead the Parkinson’s programme of work.

 My research interests are Parkinson’s disease and other neurodegenerative disorders, particularly early identification and epidemiological aspects, including environmental, clinical and genetic determinants. I am the co-principal investigator of the PREDICT-PD study, principal investigator for the East London Parkinson’s Disease project and chief investigator for the Access-PD study. I am a member of the International Parkinson and Movement Disorder Society (MDS). I graduated from the MDS LEAP leadership programme in 2020, and then became a member of the faculty for the LEAP, teaching leadership skills to early career movement disorders specialists around the world. I am the Chair of the MDS Epidemiology Study Group, a member of the MDS Early Onset PD Task Force, and sit on the MDS Prodromal Parkinson’s Subcommittee. I also sit on the Executive Steering Committee of the Global Parkinson’s Genetics Program (GP2) and lead one of its working groups, focusing on Training and Networking. I am the Chair of the Think Brain Health Global initiative and Associate Editor for the Journal of Parkinson’s Disease. Away from neurodegenerative disease, I am interested in the emerging link between recreational use of nitrous oxide (laughing gas) and neurological harm. I am a member of the Advisory Council for the Misuse of Drugs, who are advising the government on this matter. I have led the drafting of national guidance for managing the range of neurological conditions associated with nitrous oxide, as well as describing the clinical manifestations in patients in order to raise awareness amongst healthcare workers.


Research Interests:




Predictive models

Clinical research



    Cristina Simonet, Martin Escudero Foundation, Motor Prodromes of Parkinson's Disease

    Brook Huxford, Wolfson PhD studentship, Remote Biomarkers for Parkinson's Disease

    Jonggeol Kim, Global Parkinson's Genetics Programme, Genetic Determinants of Parkinson's Disease

    Benjamin Jacobs (subsidiary supervisor), MRC, Genetic Association study in individuals of Diverse Ancestral backgrounds with Multiple Sclerosis (ADAMS)

    Back to top